...
首页> 外文期刊>Hereditas >Novel genetic alteration in congenital melanocytic nevus MAP2K1 germline mutation with BRAF somatic mutation
【24h】

Novel genetic alteration in congenital melanocytic nevus MAP2K1 germline mutation with BRAF somatic mutation

机译:先天性素细胞痣Map2K1种系突变与BRAF体细胞突变的新型遗传改变

获取原文

摘要

Congenital melanocytic nevus (CMN) represent a benign proliferative skin disease in the epidermis and dermis. CMN are historically known to be associated with activating NRAS or BRAF mutations. Melanoma frequently harbors the BRAF p.Val600Glu mutation, which is also commonly found in benign nevi. A recent study reported mutation of MAP2K1, a downstream effector of the RAS-RAF-MEK pathway, in melanoma with an overall frequency of 8%. Later, in 2019, Jansen P detected one activating MAP2K1 mutation in acral nevi. However, it is unknown whether MAP2K1 mutations are common in CMN, and how MAP2K1 contributes to the pathogenesis of CMN remains to be determined. In this study, we report one patient clinically and histologically diagnosed with CMN, with the MAP2K1 germline mutation and a BRAF p.Val600Glu somatic hit in the lesion. To the best of our knowledge, this is the first report of the coexistence of mutated BRAF and MAP2K1 in CMN, which may suggest that MAP2K1 mutations contribute to the occurrence and development of nevus expanding our knowledge of the genetics of CMN.
机译:先天性黑素细胞痣(CMN)代表表皮和真皮中的良性增殖性皮肤病。历史上,CMN已知与激活NRAS或BRAF突变相关联。黑色素瘤经常留下BRAF P.VAL600GLU突变,这也常见于良性奈维。最近的一项研究报告了MAP2K1,RAS-RAF-MEK途径的下游效应器的突变,在黑色素瘤中,整体频率为8%。后来,2019年,Jansen P检测了acral Nevi中的一个激活MAP2K1突变。然而,尚不清楚MAP2K1突变在CMN中是否常见,并且MAP2K1如何达到CMN的发病机制仍有待确定。在这项研究中,我们在临床上报告一名患者并组织学诊断为CMN,用MAP2K1种系突变和BRAF P.VAL600GLU在病变中击中。据我们所知,这是CMN中突变BRAF和MAP2K1共存的第一个报告,这可能表明MAP2K1突变导致痣的发生和发展,扩大了我们对CMN遗传学的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号